ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer.

导出原文传递

翻译打印收藏纠错

作者： S,Filetti ^[1] ; C,Durante ^[2] ; D M,Hartl ^[3] ; S,Leboulleux ^[4] ; L D,Locati ^[5] ; K,Newbold ^[6] ; M G,Papotti ^[7] ; A,Berruti ^[8] ; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

作者单位： School of Health, Unitelma Sapienza University of Rome, Rome. ^[1] Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy. ^[2] Department of Head and Neck Oncology, Gustave Roussy, Villejuif; Université Paris Saclay, Villejuif. ^[3] Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Villejuif, France; Division of Endocrinology, Diabetes, Nutrition and Therapeutic Patient Education, Geneva University Hospitals, Geneva, Switzerland. ^[4] Translational Oncology, IRCCS ICS Maugeri, Pavia; Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy. ^[5] Thyroid Unit, The Royal Marsden NHS Foundation Trust, London, UK. ^[6] Department of Pathology, University of Turin, Turin. ^[7] Department of Medical and Surgical Specialties Radiological Sciences, and Public Health, Medical Oncology, University of Brescia at ASST Spedali Civili, Brescia, Italy. ^[8]

关键词 anaplastic thyroid cancer follicular thyroid cancer medullary thyroid cancer papillary thyroid cancer targeted therapy

主题词腺癌, 滤泡性(Adenocarcinoma, Follicular);人类(Humans);甲状腺肿瘤(Thyroid Neoplasms)

DOI 10.1016/j.annonc.2022.04.009

PMID 35491008

发布时间 2023-11-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交